Crescita Therapeutics Inc

(CRRTF, OTCGREY)

$0.73

-$0.01
(-0.01%)
PE Ratio
0.00
EPS
-$0.38
Market Cap
$15M
52 Week Range
$0.31 - $0.79
Operating Margin
0.00%
Dividend & Yield
$0.00 (0.00%)
Volume
NaN
Rev. per Share
$0.00

About Crescita Therapeutics Inc

Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases, and their symptoms in Canada, the United States, and internationally. It owns various proprietary drug delivery platforms, including DuraPeel and MMPE that support the development of patented formulations, which facilitate the delivery of active drugs into or through the skin. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; Flexicaine, an anesthetic formulation of lidocaine and tetracaine for the topical treatment of pain conditions; MiCal 1 that is in Phase II clinical trial for the treatment of moderate to severe plaque psoriasis; and MiCal 2, which is in preclinical stage to treat a dermatological skin condition. Its non-prescription skincare products comprise skincare products for aging, acne, rosacea, pigmentation, dehydration, and sensitivity under the Laboratoire Dr Renaud brand; a line of cosmeceutical products for anti-aging medical procedures under the Pro-Derm brand; and a line of products to target and treat various skincare concerns under the Alyria brand. The company has a collaboration agreement with Tetra Natural Health to develop Tetra's dermatology portfolio using the company's transdermal delivery technologies, multiplexed molecular penetration enhancer and DuraPeel; and a development and licensing agreement with Sundial Growers Inc. to develop cannabis and hemp topicals. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.

Earnings

News about Crescita Therapeutics Inc

Crescita Therapeutics Inc

Type
Sector
Industry
About kinfo
Kinfo is an app for DIY traders and investors. Kinfo tracks your trading performance and lets you compare measurable performance metrics against other traders. Kinfo works for day trading, swing trading and longer holding periods. By tracking portfolio performance kinfo allows traders to learn, find inspiration and gain confidence.
Get Social
Download the App

Trading involves significant risk of loss. It is not suitable for all investors and you should make sure you understand the risks involved, seeking independent advice if necessary.

Never risk more than you are willing to lose. Trading futures and other derivatives may cause losses that exceed deposits.

Hypothetical performance results have inherent limitations, some of which are described below. Kinfo makes no representation that any trading account will or is likely to achieve profits or losses like those shown. There are often sharp differences between hypothetical trading performance results and the actual results subsequently achieved by any trading program. Past results of advertised trading systems, profit statements, charts or any other representations are not indicative of future performance.

Kinfo is an educational site and is not a financial adviser or broker. All stocks, ETFs, commodities, Indices, Forex, Bonds, and other securities mentioned in our courses are for educational and illustrative purposes only. If you need professional investment advice, please consult a registered investment adviser. Futures and Options carry risk and may not be suitable for everyone.

Kinfo demonstrates specific advanced approaches (or methods). Any mention of Return of Investment percentages is only indicative of the potential of the strategy or the system and is not meant to signify any guaranteed returns.

Success in trading involves a range of human factors like decision making skills, adjustment skills, emotional control, and risk management and other psychological and behavioral parameters, all of which are completely in the hands of the individual. Trading involves significant risk of loss. It is not suitable for all investors.

Charts on kinfo provided by TradingView